


FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 12152.55US01	Application Number: 09/272,821
	Applicant: UCKUN	
	Filing Date: 03/20/1999	Group Art Unit: 1614




U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
b	5,593,993	01/14/1997	Morin, Jr. et al.	514	207	
b	5,658,907	08/19/1997	Morin, Jr. et al.	514	207	
b	5,686,428	11/11/1997	Eriksson et al.	514	80	
b	5,714,503	02/03/1998	Morin, Jr. et al.	514	332	
b	5,786,462	07/28/1998	Schneider et al.	530	23.1	


FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
44	WO 93/03022	02/18/1993	PCT	C07D	277/38		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
b		Ahgren, C. et al., "The PETT series, a new class of potent nonnucleoside inhibitors of human immunodeficiency virus Type 1 reverse transcriptase", <i>Antimicrob. Agents Chemother.</i> , Vol. 39, No. 6, pp. 1329-1335 (June 1995)
b		Artico, M. et al., "3,4-Dihydro-2-alkoxy-6-benzyl-4-oxypyrimidines (DABOs): a new class of specific inhibitors of human immunodeficiency virus Type 1", <i>Antiviral Chem. Chemother.</i> , Vol. 4, No. 6, pp. 361-368 (1993)
b		Baba, M. et al., "Highly potent and selective inhibition of HIV-1 replication by 6-phenylthiouracil derivatives", <i>Antiviral Res.</i> , Vol. 17, No. 4, pp. 245-264 (April 1992)
b		Balzarini, J. et al., "2',5'-Bis-O-(tert-butylidimethylsilyl)-3'-spiro-5"-(4"-amino-1",2"-oxathiole-2",2"-dioxide)pyrimidine (TSAO) nucleoside analogues: Highly selective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 89, No. 10, pp. 4392-4396 (May 1992)
b		Barlett, P.A., et al., "Caveat: A program to facilitate the structure-derived design of biologically active molecules", <i>Molecular Recognition in: Chemical and Biochemical Problems</i> , Special Publication No. 78, pp. 182-196 (April 1989)
b		Bell, F.W. et al., "Phenethylthiazoethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relationship studies of PETT analogs", <i>J. Med. Chem.</i> , Vol. 38, No. 25, 4929-4936 (1995)
b		Blaney, J.M. et al., "A good ligand is hard to find: Automated docking methods", <i>Perspectives in Drug Discovery and Design</i> , Vol. 1, No. 2, pp. 301-319 (December 1993))
b		Böhm, H., "The computer program LUDI: A new method for the de novo design of enzyme inhibitors", <i>Journal of Computer-Aided Molecular Design</i> , Vol. 6, No. 1, pp. 61-78 (February 1992)
b		Böhm, H., "LUDI: rule-based automatic design of new substituents for enzyme inhibitor leads", <i>Journal of Computer-Aided Molecular Design</i> , Vol. 6, No. 6, pp. 593-606 (December 1992)
b		Böhm, H., "The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure", <i>Journal of Computer-Aided Molecular Design</i> , Vol. 8, No. 3, pp. 243-256 (June 1994)
b		Bosworth, N., et al., "Scintillation proximity assay", <i>Nature</i> , Vol. 341, No. 6238, pp. 167-168 (September 14, 1989)
b		Burkert, U. et al., "Methods for the computation of molecular geometry", <i>Molecular Mechanics</i> , ACS Monograph 177, American Chemical Society, Chapter 3, pp. 59-78 (1982)
b		Brooks, B.R. et al., "CHARMM: A program for macromolecular energy, minimization, and dynamics calculations", <i>J. Comp. Chem.</i> , Vol. 4, No. 2, pp. 187-217 (1983)


EXAMINER	DATE CONSIDERED 7/20/00
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)			Docket Number:	Application Number:
			12152.55US01	09/272,821
	Applicant: UCKUN			
	Filing Date: 03/20/1999	Group Art Unit: 1614		

15	Cantrell, A.S. et al., "Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. synthesis and further structure-activity relationship studies of PETT analogs", <i>J. Med. Chem.</i> , Vol. 39, No. 21, pp. 4261-4274 (October 1996)
17	Connolly, M.L., "Solvent-Accessible Surfaces of Proteins and Nucleic Acids", <i>Science</i> , Vol. 221, No. 4612, pp. 709-713 (August 19, 1983)
18	Danel, K. et al., "Synthesis and potent Anti-HIV-1 activity of novel 6-benzyluracil analogues of 1-[2-hydroxyethoxy)methyl]-6-(phenylthio)thymine", <i>J. Med. Chem.</i> , Vol. 39, No. 12, pp. 2427-2431 (1996)
19	Danel, K. et al., "Anti-HIV active naphthyl analogues of HEPT and DABO", <i>Acta Chemica Scandinavica</i> , Vol. 51, No. 3(S), pp. 426-430 (March 1997)
20	Danel, K. et al., "Synthesis and Anti-HIV-1 activity of novel 2,3-dihydro-7H-thiazolo[3,2- α] pyrimidin-7-ones", <i>J. Med. Chem.</i> , Vol. 41, No. 2, pp. 191-198 (1998)
21	Das, K. et al., "Crystal Structures of 8-Cl and 9-Cl TIBO Complexed with Wild-type HIV-1 RT and 8-Cl TIBO Complexed with the Tyr181Cys HIV-1 RT Drug-resistant Mutant", <i>J. Mol. Biol.</i> , Vol. 264, No. 5, pp. 1085-1100 (December 20, 1996)
22	De Clercq, E., "HIV Inhibitors Targeted at the Reverse Transcriptase", <i>AIDS Research and Human Retroviruses</i> , Vol. 8, No. 2, pp. 119-134 (February 1992)
23	Ding, J., "Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors", <i>Nat. Struct. Biol.</i> , Vol. 2, No. 5, pp. 407-415 (May 1995)
24	Erice, A. et al., "Anti-Human Immunodeficiency Virus Type 1 Activity of an Anti-CD4 Immunoconjugate Containing Pokeweed Antiviral Protein", <i>Antimicrob. Agents Chemother.</i> , Vol. 37, No. 4, pp. 835-838 (April 1993)
25	Esnouf, R.M. et al., "Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor", <i>Proc. Natl. Acad. Sci. U.S.A.</i> , Vol. 94, No. 8, pp. 3984-3989 (April 15, 1997)
26	Goodsell, D.S. et al., "Automated Docking of Substrates to Proteins by Simulated Annealing", <i>PROTEINS: Structure, Function, and Genetics</i> , Vol. 8, pp. 195-202 (1990)
27	Greene, W.C., "The molecular biology of human immunodeficiency virus type 1 infection", <i>New England Journal of Medicine</i> , Vol. 324, No. 5, pp. 308-317 (January 31, 1991)
28	Heinisch, G. et al., "The inhibitory activity of diazanyl-substituted thiourea derivatives on human immunodeficiency virus type 1 reverse transcriptase", <i>Antiviral Chemistry & Chemotherapy</i> , Vol. 8, No. 5, pp. 443-446 (September 1997)
29	Hopkins, A.L. et al., "Complexes of HIV-1 Reverse Transcriptase with Inhibitors of the HEPT Series Reveal Conformational Changes Relevant to the Design of Potent Non-Nucleoside Inhibitors", <i>J. Med. Chem.</i> , Vol. 39, No. 8, pp. 1589-1600 (1996)
30	Hsiou, Y. et al., "Structures of Tyr188Leu Mutant and Wild-type HIV-1 Reverse Transcriptase Complexed with the Non-nucleoside Inhibitor HBY 097: Inhibitor Flexibility is a Useful Design Feature for Reducing Drug Resistance", <i>J. Mol. Biol.</i> , Vol. 284, No. 2, pp. 313-323 (November 27, 1998)
31	Huang, H. et al., "Structure of a Covalently Trapped Catalytic Complex of HIV-1 Reverse Transcriptase: Implications for Drug Resistance", <i>Science</i> , Vol. 282, No. 5394, pp. 1669-1675 (November 27, 1998)
32	Jones, T.A. et al., "Improved Methods for Building Protein Models in Electron Density Maps and the Location of Errors in these Models", <i>Acta Cryst.</i> , Vol. A47, Part 2, pp. 110-119 (March 1, 1991)
33	Kohlstaedt, L.A. et al., "Crystal Structure at 3.5 Å Resolution of HIV-1 Reverse Transcriptase Complexed with an Inhibitor", <i>Science</i> , Vol. 256, pp. 1783-1790 (June 26, 1992)
34	Kroeger Smith, M.B. et al., "Molecular modeling studies of HIV-1 reverse transcriptase nonnucleoside inhibitors: Total energy of complexation as a predictor of drug placement and activity", <i>Protein Science</i> , Vol. 4, pp. 2203-2222 (1995)
35	Kuntz, I.D. et al., "A Geometric Approach to Macromolecule-Ligand Interactions", <i>J. Mol. Biol.</i> , Vol. 161, No. 2, pp. 269-288 (October 25, 1982)

EXAMINER	DATE CONSIDERED
	7/20/00
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	


FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 12152.55US01	Application Number: 09/272,821
	Applicant: UCKUN	
	Filing Date: 03/20/1999	Group Art Unit: 1614



5	Larder, B.A. et al., "Convergent combination therapy can select viable multidrug-resistant HIV-1 <i>in vitro</i> ", <i>Nature</i> , Vol. 365, No. 6445, pp. 451-453 (September 30, 1993)
5	Luty, B.A. et al., "A Molecular Mechanics/Grid Method for Evaluation of Ligand-Receptor Interactions", <i>J. Comp. Chem.</i> , Vol. 16, No. 4, pp. 454-464 (April 1995)
5	Mai, A. et al., "Synthesis and Anti HIV-1 Activity of Thio Analogues of Dihydroalkoxybenzoxypyrimidines", <i>J. Med. Chem.</i> , Vol. 38, No. 17, 3258-3263 (August 18, 1995)
7	Mai, A. et al., "Dihydro(alkylthio)(naphthylmethyl)oxypyrimidines: Novel Non-Nucleoside Reverse Transcriptase Inhibitors of the S-DABO Series", <i>J. Med. Chem.</i> , Vol. 40, No. 10, pp. 1447-1454 (May 9, 1997)
7	Mao, C. et al., "Structure-based design of N-[2-(1-piperidinylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea and N-[2-(1-piperazinylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea as potent non-nucleoside inhibitors of HIV-1 reverse transcriptase", <i>Bioorg. Med. Chem. Lett.</i> , Vol. 8, pp. 2213-2218 (1998)
5	Mao, C. et al., "Rational Design of N-[2-(2,5-Dimethoxyphenylethyl)]-N'-[2-(5-Bromopyridyl)]-Thiourea (HI-236) as a Potent Non-Nucleoside Inhibitor of Drug-Resistant Human Immunodeficiency Virus", <i>Bioorganic & Medicinal Chemistry Letters</i> , Vol. 9, No. 11, pp. 1593-1598 (June 7, 1999)
7	Marshall, G.R. "Computer-Aided Drug Design", <i>Ann. Rev. Pharmacol. Toxicol.</i> , Vol. 27, pp. 193-213 (1987)
5	Martin, Y.C., "3D Database Searching in Drug Design", <i>J. Med. Chem.</i> , Vol. 35, No. 12, pp. 2145-2154 (June 12, 1992)
5	Massa, S. et al., "Synthesis and antiviral activity of new 3,4-dihydro-2-alkoxy-6-benzyl-4-oxypyrimidines (DABOs), specific inhibitors of human immunodeficiency virus type 1", <i>Antiviral Chem. Chemother.</i> , Vol. 6, No. 1, pp. 1-8 (January 1995)
7	Miles, S., "Introduction", <i>J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.</i> , Vol. 16, Suppl. 1, pp. S1-S2 (1997)
5	Mitsuya, H. et al., "Molecular Targets for AIDS Therapy", <i>Science</i> , Vol. 249, pp. 1533-1544 (September 28, 1990)
5	Nishibata, Y. et al., "Automatic Creation of Drug Candidate Structures Based on Receptor Structure. Starting Point for Artificial Lead Generation", <i>Tetrahedron</i> , Vol. 47, No. 43, pp. 8985-8990 (November 4, 1991)
5	Nunberg, J.H. et al., "Viral Resistance to Human Immunodeficiency Virus Type 1-Specific Pyridinone Reverse Transcriptase Inhibitors", <i>J. Virol.</i> , Vol. 65, No. 9, pp. 4887-4892 (September 1991)
5	Pauwels, R. et al., "Potent and selective inhibition of HIV-1 replication <i>in vitro</i> by a novel series of TIBO derivatives", <i>Nature</i> , Vol. 343, No. 6257, pp. 470-474 (February 1, 1990)
5	Pontikis, R. et al., "Synthesis and Anti-HIV Activity of Novel N-1 Side Chain-Modified Analogs of 1-[(2-Hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT)", <i>J. Med. Chem.</i> , Vol. 40, No. 12, pp. 1845-1854 (1997)
7	Remington's Pharmaceutical Sciences, Chapter 43, 14 th Ed., Mack Publishing Co., Easton, PA 18042, USA, "Topical Drugs", pp. 763-786 (Date Unknown)
5	Ren, J. et al., "High resolution structures of HIV-1 RT from four RT-inhibitor complexes", <i>Nat. Struct. Biol.</i> , Vol. 2, No. 4, pp. 293-302 (April 1995)
5	Ren, J. et al., "The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design", <i>Structure</i> , Vol. 3, No. 9, pp. 915-926 (1995)
5	Richman, D. et al., "Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 88, No. 24, pp. 11241-11245 (December 15, 1991)
5	Romero, D.L. et al., "Bis(heteroaryl)piperazine (BHAP) Reverse Transcriptase Inhibitors: Structure-Activity Relationships of Novel Substituted Indole Analogues and the Identification of 1-[(5-Methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3-[(1-methylethyl)amino]-pyridinyl]piperazine Monomethanesulfonate (U-90152S), a Second-Generation Clinical Candidate", <i>J. Med. Chem.</i> , Vol. 36, No. 10, pp. 1505-1508 (1993)
5	Sahlberg, C. et al., "Synthesis and Anti-HIV Activities of Urea-PETT Analogs Belonging to a New Class of Potent Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors", <i>Bioorganic & Medicinal Chemistry Letters</i> , Vol. 8, No. 12, pp. 1511-1516 (June 16, 1998)

EXAMINER	DATE CONSIDERED 7/20/00
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 12152.55US01	Application Number: 09/272,821
	Applicant: UCKUN	
	Filing Date: 03/20/1999	Group Art Unit: 1614



5	Sudbeck, E.A. et al., "Structure-Based Design of Novel Dihydroalkoxybenzoxypyrimidine Derivatives as Potent Nonnucleoside Inhibitors of the Human Immunodeficiency Virus Reverse Transcriptase", <i>Antimicrob. Agents Chemother.</i> , Vol. 42, No. 12, pp. 3225-3233 (December 1998)
7	Tanaka, H. et al., "A New Class of HIV-1-Specific 6-Substituted Acyclouridine Derivatives: Synthesis and Anti-HIV-1 Activity of 5- or 6- Substituted Analogues of 1-[(2-Hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT)" <i>J. Med. Chem.</i> , Vol. 34, No. 1, pp. 349-357 (1991)
13	Tantillo, C. et al., "Locations of Anti-AIDS Drug Binding Sites and Resistance Mutations in the Three-dimensional Structure of HIV-1 Reverse Transcriptase", <i>J. Mol. Biol.</i> , Vol. 243, No. 3, pp. 369-387 (October 28, 1994)
17	Tramontano, E. et al., "Characterization of the anti-HIV-1 activity of 3,4-dihydro-2-alkoxy-6-benzyl-4-oxypyrimidines (DABOs), new non-nucleoside reverse transcriptase inhibitors", <i>Microbiologica</i> , Vol. 17, pp. 269-279 (1994)
19	Uckun, F.M. et al., "TXU (Anti-CD7)-Pokeweed Antiviral Protein as a Potent Inhibitor of Human Immunodeficiency Virus", <i>Antimicrob. Agents and Chemother.</i> , Vol. 42, No. 2, pp. 383-388 (February 1998)
17	Vig, R. et al., "Rational Design and Synthesis of Phenethyl-5-bromopyridyl Thiourea Derivatives as Potent Non-nucleoside Inhibitors of HIV Reverse Transcriptase", <i>Bioorg. Med. Chem.</i> , Vol. 6, pp. 1789-1797 (1998)
18	Vig, R. et al., "5-alkyl-2-[(methylthiomethyl)thio]-6-(benzyl)-pyrimidin-4-(1H)-ones as potent non-nucleoside reverse transcriptase inhibitors of S-DABO series", <i>Bioorg. & Med. Chem. Lett.</i> , Vol. 8, pp. 1461-1466 (1998)
17	Weiner, S.J. et al., "A New Force Field for Molecular Mechanical Simulation of Nucleic Acids and Proteins", <i>J. Am. Chem. Soc.</i> , Vol. 106, pp. 765-784 (1984)
18	Zarling, J.M. et al., "Inhibition of HIV replication by pokeweed antiviral protein targeted to CD4 ⁺ cells by monoclonal antibodies", <i>Nature</i> , Vol. 347, No. 6288, pp. 92-95 (September 6, 1990)
18	Zhang, H. et al., "Inhibition of human immunodeficiency virus type 1 wild-type and mutant reverse transcriptases by the phenyl ethyl thiazolyl thiourea derivatives trovirdine and MSC-127", <i>Antiviral Res.</i> , Vol. 28, No. 4, pp. 331-342 (1995)
17	Zhang, H. et al., "Synergistic inhibition of HIV-1 reverse transcriptase and HIV-1 replication by combining trovirdine with AZT, ddI and ddC in vitro", <i>Antiviral Chem. & Chemother.</i> , Vol. 7, No. 5, pp. 221-229 (1996)

EXAMINER	DATE CONSIDERED 4/20/00
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	